母胎医学会声明:对美国食品药品监督管理局撤销17-α羟孕酮己酸酯的回应
2023年4月5日,美国食品药品监督管理局因缺乏降低复发性自发性早产风险的证据,立即撤销17-α羟孕酮己酸酯所有剂型的批准。母胎医学会同意该决定,不鼓励继续处方该药(包括通过配制药房),并建议不改变宫颈环扎指征、短宫颈阴道孕酮指征或活动限制建议。
要点
- FDA于2023年4月5日立即撤销17-α羟孕酮己酸酯所有剂型(肌注和皮下)的批准。
- SMFM同意FDA决定,不鼓励继续处方该药,包括通过配制药房。
- 不推荐基于此次撤市改变宫颈环扎指征、短宫颈阴道孕酮指征或反对活动限制的建议。
核心结论
- 母胎医学会同意FDA因缺乏降低复发性自发性早产风险的证据而撤销17-α羟孕酮己酸酯的批准,不鼓励继续处方该药。
研究设计与样本
- 母胎医学会声明,针对FDA于2023年4月5日撤销17-α羟孕酮己酸酯批准的决定作出回应。
主要发现
- FDA撤销17-α羟孕酮己酸酯所有剂型(肌注和皮下)的批准,适用于品牌药(Makena)和仿制药。
- FDA认为延迟撤市生效以允许正在治疗的患者完成治疗不合适,母胎医学会同意继续治疗无获益证据。
- FDA药物评价与研究中心未发现妊娠37周前停药有害的证据。
关键数值与推荐
- 不推荐基于FDA撤市改变宫颈环扎指征、短宫颈患者阴道孕酮指征或反对活动限制的建议。
- 推荐对无宫颈长度信息或宫颈长度≥25 mm者讨论阴道孕酮用于复发性早产一级预防时纳入共享决策,尤其既往妊娠曾接受孕酮制剂预防早产者。
临床怎么用
- 不鼓励继续处方17-α羟孕酮己酸酯,包括通过配制药房。
- 正在接受17-α羟孕酮己酸酯的患者可被告知FDA药物评价与研究中心未发现妊娠37周前停药有害的证据。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
On April 5, 2023, the US Food and Drug Administration withdrew the approval of 17-alpha hydroxyprogesterone caproate, effective immediately, because of the lack of evidence that it reduces the risk of recurrent spontaneous preterm birth. This decision withdraws approval for all formulations of 17-alpha hydroxyprogesterone caproate (both intramuscular and subcutaneous) and applies to both brand name (Makena) and generic versions of the medication. We agree with the Food and Drug Administration determination and discourage continued prescribing of 17-alpha hydroxyprogesterone caproate, including through compounding pharmacies. We do not recommend changing indications for cerclage, indications for vaginal progesterone in patients with a short cervix, or recommendations against activity restriction based on the Food and Drug Administration withdrawal of 17-alpha hydroxyprogesterone caproate from the market. We recommend that discussion of the use of vaginal progesterone for primary prevention of recurrent preterm birth without input of cervical length or in those with a cervical length of ≥25 mm includes a shared decision-making process, especially if a progesterone formulation for preterm birth prevention was received in a previous pregnancy. The Food and Drug Administration determined that it would be inappropriate to delay the effective date of the withdrawal to allow patients currently receiving 17-alpha hydroxyprogesterone caproate to finish treatment. We agree with the Food and Drug Administration that there is no evidence of benefit with continued treatment. Patients currently receiving 17-alpha hydroxyprogesterone caproate can be counseled that the Food and Drug Administration's Center for Drug Evaluation and Research has not identified evidence of harm from discontinuation before 37 weeks of gestation.
引用
- Society for Maternal-Fetal Medicine Statement: Response to the Food and Drug Administration's withdrawal of 17-alpha hydroxyprogesterone caproate. Am J Obstet Gynecol. 2023. PMID: 37061078. doi:10.1016/j.ajog.2023.04.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。